



HHS Public Access

Author manuscript

Mol Psychiatry. Author manuscript; available in PMC 2021 May 13.

Published in final edited form as:

Mol Psychiatry. 2021 January ; 26(1): 41–50. doi:10.1038/s41380-020-00949-3.

Polysubstance Use in the US Opioid Crisis

Wilson M. Compton, M.D., M.P.E.^{1,*}, Rita J. Valentino, Ph.D.¹, Robert L. DuPont, M.D.²

¹National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Service

²Institute for Behavior and Health, Inc

Abstract

Interventions to address the U.S. opioid crisis primarily target opioid use, misuse, and addiction, but because the opioid crisis includes multiple substances, the opioid-specificity of interventions may limit their ability to address the broader problem of polysubstance use. Overlap of opioids with other substances ranges from shifts among the substances used across the lifespan to simultaneous co-use of substances that span similar and disparate pharmacological categories. Evidence suggests that non-medical opioid users quite commonly use other drugs, and this polysubstance use contributes to increasing morbidity and mortality. Reasons for adding other substances to opioids include enhancement of the high (additive or synergistic reward), compensation for undesired effects of one drug by taking another, compensation for negative internal states, or a common predisposition that is related to all substance consumption. But consumption of multiple substances may itself have unique effects. To achieve the maximum benefit, addressing the overlap of opioids with multiple other substances is needed across the spectrum of prevention and treatment interventions, overdose reversal, public health surveillance, and research. By addressing the multiple patterns of consumption and the reasons that people mix opioids with other substances, interventions and research may be enhanced.

Introduction

The U.S. opioid crisis exerts a major impact on health and social outcomes. Since 2005, deaths due to opioid overdoses exceed 500,000,¹ and declines in overall U.S. life expectancy are at least partly explained by overdose mortality.^{2,3} Morbidity caused by opioids includes increasing infectious disease (particularly HIV, hepatitis, and endocarditis), sleep disorders, affective disorders, and increasing neonatal opioid withdrawal, among other outcomes.⁴⁻⁹

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

*Corresponding Author: Wilson M. Compton, M.D., M.P.E., 6001 Executive Blvd., MSC 9581, Bethesda, MD 20892-9581, USA, Phone: 301-443-6480, wcompton@nida.nih.gov.

Disclaimers

The findings and conclusions of this study are those of the authors and do not necessarily reflect the views of the National Institute on Drug Abuse of the National Institutes of Health, the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services.

Competing Interests

W.M.C. reports ownership of stock in General Electric, 3M, and Pfizer Inc. unrelated to the submitted work. Other authors have no interests to declare.

Overall economic impact from opioid misuse was estimated at \$500 billion per year in 2017.¹⁰

In response, prevention and treatment practices and policies have been implemented widely.^{5,11} These include expanding access to medications for opioid use disorder (OUD),^{12–15} reducing opioid prescribing,^{16–19} increasing access to naloxone,^{20–24} improving public health surveillance,¹⁶ increasing access to harm reduction programs such as syringe services,^{16,25,26} and major investments in research.^{27,28} All of these interventions target opioid use, misuse, and addiction. However, if the “opioid crisis” includes multiple substances, the opioid- specificity of current prevention and treatment interventions may limit their ability to address the broader problem of polysubstance use involving opioids. To have the maximum impact on this multifaceted crisis, it is important to understand the overlap of opioids with other substances.

Overlap of opioids with other substances can include shifts across the lifespan and simultaneous co-use of substances. Use of substances across a broad time frame (i.e. past year or lifetime) is typical for epidemiological studies, which less commonly assess specific co-use patterns within specific drug using occasions. However, the primary focus of this *Perspective* is on the issue of simultaneous co-use of an opioid with another substance, which could include nicotine, alcohol, other opioids including prescribed opioids, benzodiazepines (and other sedatives), stimulants including cocaine and amphetamine-related compounds, and other categories.

There are multiple reasons people use other substances with opioids: enhancement of the high (additive or synergistic reward), compensation for undesired effects of one drug by taking another, compensation for negative internal states, or a general predisposition for all substances. The possibility that consuming multiple substances in combination has additive or synergistic pharmacological effects particularly demands study. Fortunately, we are now at a point where advances in research methods allow us to study these kinds of complexities, moving addiction science beyond the typically single-drug models of the past.

In this *Perspective*, we summarize overlaps of opioid use and addiction with use of and addiction to other substances from viewpoints of population science and then neuroscience. In each section we address questions of why non-medical opioid users also commonly use other drugs, and what are health consequences of simultaneous use of multiple drugs, including their role in overdose deaths.

Population Studies

Epidemiological studies dating back at least several decades confirm that persons with OUD are likely to have used multiple substances, not just opioids. The Epidemiologic Catchment Area data from the early 1980s showed that, on average, heroin users consumed 5.0 other illicit substances (out of 7 categories assessed and excluding tobacco or alcohol) and users of opioids other than heroin consumed 5.8 others.²⁹ Results from observational studies of returning Vietnam Veterans and samples of heroin users in Miami and California confirm

other drug use as a prominent risk factor for subsequent heroin use and overlapping co-use of heroin with other substances.³⁰⁻³⁴

More recent studies also have documented that opioid use overlaps with other substances and that OUD often co-occurs with other substance use disorders.³⁵⁻³⁸ A 2012–2013 U.S. general population study found that more than 90 percent of individuals with OUD used more than two other substances within the same year, and over 25 percent had at least two other substance use disorders along with OUD.³⁹ Those with more substance use disorders were more likely to be younger, male, and single and were more likely to have initiated opioid use at an earlier age.³⁹ Finally, a notable indicator of simultaneous multi-substance use is that the majority of opioid-related overdose deaths involve multiple substances (see Health and Safety Consequences below).

While overlap with other substances and substance use disorders is common among those with OUD, the patterns may vary.⁴⁰ Recent evidence shows an increasing rate of methamphetamine use among adults in the U.S. admitted to treatment programs for heroin addiction.⁴¹ The implication is that overlap of opioids with other substances is common but can vary across time, both within an individual and within populations of users.

While the focus of this *Perspective* is on polysubstance use in the context of opioids, it is important to consider that polysubstance use frequently occurs with all recreational drugs, whether their use is legal or illegal. Cigarette smokers are far more likely to drink alcohol than non-smokers. Marijuana users are far more likely to use opioids nonmedically than people who do not use marijuana. This pattern is seen in all ages and drug-using populations.⁴² Further, as a general principal, the more widely a drug is used, the higher the percentage of users who do not use other drugs; and, the less widely used, the more likely a drug is to be used with other drugs (Figure 1). While the reasons for this increasing overlap in substances that are less frequently consumed isn't totally clear, some of it may relate to the drug use trajectories where substances are added to one another in a progression. Because less frequently consumed substances are rarely the first used, it is typical that less frequently consumed substances would have a higher degree of overlap over the life-course than the more commonly consumed. This principal may help explain the high frequency of overlap of heroin use with other drug use and the lesser, but still significant, overlap of prescription opioid misuse (which is much more common than heroin use) with other drug use.

Compensation for negative internal states

Polysubstance use, including when it involves opioids, may be a way to compensate for negative internal states associated with psychiatric disorders (maladaptive self-medication). Mental illnesses, especially mood disorders, often co-occur with opioid use and use disorders.^{35,37} Of the 9.6 million American adults who misused opioids in 2018, 45.8% (4.4 million) had a mental illness in the past year, and 17.3% (1.7 million) had a serious mental illness in the past year.⁴³ The rates of co-occurring mental illness are even higher for those with a past-year OUD, with 66.7% having any mental illness in the past year and 28.6% having serious mental illness in the past year.⁴³ In 2018, 17.3% of the adults who had misused opioids (1.6 million people) reported having serious thoughts of suicide, 6.6% (0.6

million) made suicide plans, and 3.2% (0.3 million) attempted suicide.⁴³ In one study individuals with substance use disorders involving multiple drugs were more likely to have other mental illnesses than were those with just OUD.³⁹ In particular, polysubstance use may have contributed to post traumatic stress disorder because of its deleterious effects on neuroendocrine stress-response systems.³⁹

OUD is also highly comorbid with pain. Chronic pain and the associated emotional distress may dysregulate the brain's reward and stress circuitry, raising the risk for opioid misuse and OUD.⁴⁴ One study estimates that 10% of patients treated for chronic pain misuse prescription opioids.⁴⁴ The use of other drugs including alcohol, cannabis or sedatives is common in individuals with chronic pain. Although the prevalence of chronic pain is positively correlated with the number of comorbid substance use disorders, it was not found to be a significant factor in the prevalence of comorbid substance use disorders for individuals with OUD.⁴⁵ One possible explanation for this was that a greater proportion of the chronic pain/OUD group were females who are less likely to be polysubstance users. Consistent with this, in a study of individuals under treatment for substance use disorder that have chronic pain, polysubstance use was associated with pain interference only in males with alcohol use disorder.⁴⁶ Chronic pain was also found to be associated with mental health disorders, particularly mood disorders, in individuals with substance use disorders and this was highest for individuals with both OUD and chronic pain, implying important interactions between mental illness, pain and OUD.⁴⁶

Compensation for other drug effects

An incentive for polysubstance use is to compensate for impairments associated with opioid use. Just as users may perceive that co-use of stimulants ameliorates alcohol impairment, people who use opioids may take stimulants to compensate for opioids' sedating effects. One of the motivations for use of prescription opioids, stimulants, and benzodiazepines has been to "increase or decrease the effects of other drugs".^{37,47,48} For example, the addition of cocaine to decrease the dose of heroin and degree of physical dependence has been reported by out-of-treatment users and by methadone patients.⁴⁹ Such combinations of heroin and cocaine may be sought because of both the rewarding effects and as compensation for adverse opioid effects.⁵⁰

Health and Safety Consequences

Toxicity can be increased through pharmacokinetic or pharmacodynamic interactions as described in the Neuroscience section below, and drug combinations involving opioids may be particularly dangerous from the standpoint of overdose risk.^{51,52} Detailed analyses of polysubstance use in Florida identified multiple causative substances in 93% of the 1743 fentanyl-related overdose deaths in 2017.⁵³ Use of other substances appears to play a role in overdose from heroin,^{54–56} and combinations of opioids with other substances, especially sedatives and respiratory depressants such as alcohol and benzodiazepines, increase the risk of overdose.^{51,57–59}

Overdose research typically reports each category of substances separately, without accounting for overlap. For instance, the primary report on drug overdose deaths from the

National Center for Health Statistics reported on all overdose deaths combined and deaths from: 1) any opioid or 2) heroin, 3) natural and semisynthetic opioids, 4) methadone, and 5) synthetic opioids other than methadone.¹ Yet, deaths involving more than one category are coded in all that are included, perhaps masking important trends in which multiple drugs may be the culprit more than one specific drug.

Because of its very high potency and its ubiquity in mixtures with heroin and sometimes with other drugs such as cocaine or counterfeit prescription medications, polysubstance use with fentanyl may be responsible for the high fatality rate in many areas of the United States. In 2016, 79.7% of overdose deaths in the U.S. involving synthetic opioids other than methadone (i.e. fentanyl-related compounds) also involved other substances, particularly other opioids, cocaine, benzodiazepines, alcohol, psychostimulants, and antidepressants.⁶⁰ Purveyors of the drugs (i.e. the vector) may be responsible for some of the polydrug use found in overdose decedents.⁵ It may or may not have been the explicit choice of a user to combine substances, and reasons for the multiple drug use may include both intentional co-ingestion as well as adulteration of the illicit drug supply.⁶¹

Benzodiazepines are an important category to consider. By themselves, benzodiazepines have a generally limited ability to result in overdose death;⁶² however, the combination with opioids is increasingly detected in overdose deaths, suggesting synergistic effects.⁵¹ Reasons for this increased lethality of the combinations are not fully understood and may vary depending on the specific opioid and benzodiazepine involved.⁶³

Polysubstance use may also contribute to risk of traumatic injury, infectious disease risk, and other health consequences.⁶⁴ Between 40 and 60 percent of patients seen in trauma centers have alcohol or other drugs in their system, and, in one study, presence of cocaine, marijuana, or opioids in the blood was significantly more likely among injured patients with acute alcohol intoxication than in those without alcohol intoxication.⁶⁵ Furthermore, settings where patients with injuries due to polysubstance consumption are treated (including emergency and inpatient settings) can be useful in providing opportunities for intervention and engagement in care that is needed over the long term.

Neuroscience Studies

Convergent Reward Mechanisms

A neurobiological basis for polysubstance use is that combining drugs that converge on a common circuit at different points can produce additive or synergistic rewarding effects. Synergistic pharmacological interactions occur with drugs that have different mechanisms but a common end consequence, such as increasing dopamine release in the nucleus accumbens. With synergistic interactions, the effect of the combination is greater than the sum of the separate drug effects. This contrasts with additive pharmacological interactions, which occur between drugs that share a common mechanism and would result in an effect that is equal to the sum of both agents.

The rewarding effects of substances are mediated by ventral tegmental area (VTA)-dopaminergic projections to the nucleus accumbens (NAC).⁶⁶ The action of this pathway

can be enhanced by several mechanisms, including by directly or indirectly increasing activity of VTA-dopamine (DA) neurons, increasing terminal DA release, blocking DA reuptake or enhancing the post-synaptic actions of DA on NAC neurons. Preclinical studies in rodents have identified the neuronal and neurochemical actions of drugs on this circuit (see Figure 2).

Opioids are distinct from other rewarding substances through their actions at specific opioid receptors. Studies in animals indicate that activation of μ -opioid receptors on GABA-VTA cells disinhibits dopamine neurons and increases their activity and dopamine function in the NAC.⁶⁷ When opioid receptors are maximally occupied, the addition of another opioid has no further effect. However, combinations with stimulants that increase synaptic levels of dopamine or that enhance dopamine terminal release results in a synergistic effect on dopamine release that is greater than the effect of either alone.^{68,69}

Preclinical studies demonstrated that cocaine enhances dopamine levels primarily through inhibition of the dopamine transporter, whereas amphetamine-like stimulants both inhibit the transporter and also directly increase vesicular release.⁷⁰ The net effect of both is to increase dopamine in the NAC. For example, cocaine increases inhibitory GABA transmission from the prefrontal cortex to VTA-GABA neurons, an effect that would disinhibit VTA-dopamine neurons through a mechanism that is distinct from that mediated by opioid receptors.⁷¹ In addition to its primary effect to increase terminal dopamine release, amphetamine inhibits monoamine oxidase and enhances tyrosine hydroxylase, which would have the net effect of increasing dopamine extracellular levels, also in ways that are distinct from opioid mechanisms.⁷²

Although there is substantial evidence for synergistic effects of stimulant/opioid combinations on dopamine release in animals, self-administration of the combination reflected an additive interaction, i.e., it was not greater than the sum of the individual drug effects in animals.⁷³ In human laboratory studies the effects are mostly additive but this is dose-related.⁷⁴ For example, certain dose combinations increased ratings of “high” and “liking” and cocaine administered to methadone-maintained individuals produced greater subjective ratings of “high” and “liking”.^{74,75} In drug discrimination studies in non-human primates the drug combination produces a unique discriminative stimulus that shares characteristics with the individual drugs but does not completely overlap them.⁷⁶

Notably, the actions of stimulants are not limited to dopamine systems. They also increase the activation of the other monoamine systems, serotonin and norepinephrine.⁷⁰ The bias towards a particular monoamine system depends on the specific stimulant. For example, cathinones (bath salts) have a greater effect on serotonin than amphetamine, which is biased towards dopamine and norepinephrine systems.⁷⁷ The enhancement of noradrenergic function by stimulants may further drive opioid use in an effort to compensate for or balance the arousal response.

Benzodiazepines are often co-administered with opioids. Because they are allosteric modulators of GABA A receptors (GABAAR), benzodiazepines might be predicted to oppose the disinhibitory effects of opioids in the VTA. However, although both GABA and

dopamine neurons in the VTA express GABAAR, benzodiazepines bind to those containing the $\alpha 1$ subunit, which are localized to VTA-GABA neurons and are lacking in VTA-dopamine neurons.^{78–80} The resulting inhibition of VTA-GABA neurons would be additive to the acute action of opioids. In human studies, benzodiazepines enhance the subjective effects of opioids, including “high” and “liking”.⁶³ Benzodiazepines are commonly prescribed along with opioid analgesics and are commonly misused by those who use illicit opioids,^{63,81} and the combination has been implicated in increasing the risk for overdose.^{51,57,63,81} Both benzodiazepines and opioids inhibit respiration so that the effects of the combination may be additive. Although mechanisms underlying this interaction have not been elucidated, in animal models pretreatment of a benzodiazepine potentiated opioid-induced brain hypothermia, but not hypoxia, whereas co-administration of the two potentiated the opioid-induced decrease in oxygen levels in brain.⁸²

The complex rewarding effects of nicotine are mediated by multiple receptors in the VTA and NAC, although its actions at the $\beta 2$ -nAChR subtype are considered to be integral to the rewarding effects.⁸³ Unlike opioids, nicotine directly depolarizes VTA-dopamine neurons.⁸⁴ This would produce a greater magnitude of neuronal activation than disinhibition alone and would synergize with opioid disinhibition of the same neurons. In addition to increasing dopamine discharge rate, nicotine changes the pattern of discharge to favor a phasic or bursting mode.⁸⁵ This is mediated by $\alpha 7$ -nAChR enhancement of glutamatergic signaling from the prefrontal cortex to VTA-dopamine neurons.^{86,87} Dopamine bursting promotes the formation of associations between stimuli and rewards and this may be the basis for reward-enhancing effects of nicotine in combination with other substances.^{88,89}

Gateway-Priming

Typically, the term “gateway drug theory” refers to use of tobacco and alcohol preceding marijuana, followed by “harder drugs” like cocaine or opioids, and most who misuse opioids have already used legal drugs and marijuana.²⁹ An important consideration of the theory is that the gateway drug is often used during adolescence. This is a window of brain development during which perturbations such as drug exposure can produce unique and enduring effects.

While multiple studies document overlaps in substance-use onset,^{42,90} mechanisms for a gateway potential for nicotine have perhaps best been delineated. Neurobiological evidence suggests that, independent of its own rewarding effects, nicotine can intensify rewarding effects of other substances and non-drug rewards.^{89,91} In addition to the ability of nicotine to favor phasic dopamine neuronal discharge, this may also be attributed in part to its ability to increase tyrosine hydroxylase activity.^{92,93} Nicotine’s actions as a histone deacetylase inhibitor could prime a cocaine response by enhancing cocaine-related histone-4 acetylation of the FosB gene, and the hyperacetylation of other histones by nicotine would further enhance gene expression.⁹¹ Analyzing data from two cohort studies, Kandel and Kandel found that cocaine dependence was highest in users who had first smoked cigarettes and that concurrent smoking around the time of cocaine initiation was associated with more persistent cocaine use and addiction—consistent with the priming effect they found in their animal model. Conversely, cocaine does not appear to prime the nicotine response.⁹¹

Although this novel hypothesis is compelling, it awaits confirmation by other studies and the linkages to later addiction to opioids are not fully established. Future studies identifying these effects are necessary for understanding the potential for licit drug administration during adolescence to accelerate progression to illicit drug use.

Neuroplasticity

In addition to acute actions described above, all drugs of abuse produce long-term plasticity that contributes to compulsive behaviors that characterize substance use disorder. They do so through multiple mechanisms, and a description of this is beyond the scope of this *Perspective*. However, a shared mechanism through which most drugs of abuse induce enduring neuroadaptations is by increasing the AMPAR/NMDAR ratio, resulting in enhanced excitatory transmission onto VTA-dopamine neurons.^{70,94} The mechanisms by which individual drug classes produce their effects and whether these are specific to individual classes is a topic of future investigation.

Implications for Research

The study of multiple substances requires assessment of both individual and combined effects. Therefore, when multiple substances are involved a general issue is the difficulty of framing meaningful research hypotheses and selecting from a broad range of possible analyses. The National Institutes of Health provides guidance through a specific funding opportunity announcement on the importance of both observational and treatment development research on polysubstance use (see: <https://grants.nih.gov/grants/guide/pa-files/PAR-20-035.html>). Yet, not every potential interaction can be examined because of increasing research complexity, including potentially exponentially larger samples as more combinations are examined (compared to single substance studies). Furthermore, because it is recognized that studies of polysubstance use require complex designs and analysis, the grant program mentioned above includes special review (i.e. review by a specifically designated initial review group).

Priority areas where addressing polysubstance use is particularly urgent may include those combinations that are shown to have negative effects and population impacts. One specific combination for research is to understand the mechanisms of specific and apparently deadly combinations of opioids with alcohol, benzodiazepines, and other sedating agents, and some work to address these interactions is underway.⁹⁵ For other combinations, prioritization will be required. Fortunately, large-scale human studies such as the National Survey on Drug Use and Health, the Adolescent Brain Cognitive Development study, and other population studies are poised to provide data which can help to identify meaningful polysubstance use patterns.^{43,96} That is, these and other population studies can identify specific types of drug combinations that show particular relevance to human health for examination in basic research to determine mechanisms of action. Given that polysubstance use is more often the rule than the exception, novel approaches are needed to predict the multiple points of intersection of drugs that would result in a greater risk of a use disorder or toxicity from drug combinations. Likewise, novel approaches are needed to predict therapeutic measures

that go beyond targeting a single drug-receptor interaction and towards the long-term plasticity that maintains addiction.

One promising approach relies on a big data approach of developing predictive models by computational mining of datasets related to drug abuse.⁹⁷ A centralized data base of chemicals, target proteins, cellular signaling pathways, and tissues related to abused substances was recently generated from the literature and public databases, with the goal of identifying networks of interactions that would predict the consequences of polysubstance use, underlying mechanisms of these consequences, and potential means of targeting these mechanisms.⁹⁸ This approach has the potential to discover novel mechanisms of synergy by identifying common target proteins and convergent signaling pathways. As this is a relatively new approach, its utility will depend on the breadth of the database and sophistication of the computational tools, both of which will evolve with time.

We also highlight the potential importance of careful translation of preclinical research to human studies. For example, preclinical models of drug reward (i.e. Figure 2) could be updated with clinical research to identify which pathways and receptors are related to different substances in humans. Some of this work has been started in the area of unique and general brain pathway correlates of addictions to various substances,¹⁰⁰ but both new research as well as thoughtful graphical synthesis to illustrate the impacts are needed.

On a more immediate level, overdoses due to multiple substances may not respond fully to administration of naloxone, which targets only the opioid agents. Needed are both overdose-reversal agents for other substances and general approaches to support respiration. Such respiratory agents could be beneficial regardless of the overdose cause.

While sex and gender differences in polysubstance use have not been a major topic of research, sex and gender differences need to be considered in both the population and neurobiology studies. Patterns of opioid consumption and progression vary according to sex and gender and detailed analysis of these patterns for polysubstance use are needed as well to optimize individualized strategies for prevention and treatment. Additionally, sex differences can be used as a tool to elucidate the neurobiological mechanisms underlying polysubstance abuse.

Conclusions

Interventions and research to address the U.S. opioid crisis have, for the most part, targeted opioid use, misuse, and addiction specifically. Even though it is the norm in most research on drug effects to look at substances in isolation, this greatly limits our understanding and risks ignoring important synergies, including potential additive (or multiplicative) effects of multiple substances on reward and reinforcement, as well as enhanced morbidity such as overdose. To account for polysubstance use, prevention approaches may benefit from targeting universal, common factors across substances,⁹⁹ and treatment development needs to account for this polysubstance use as well. Treatment may need to focus on general factors, rather than drug-specific features. A target for treatment to address polysubstance use may be to focus on strengthening decision-making in general or targeting other common

features across substances, such as craving or use of substances as a coping mechanism. Service delivery systems may need to be modified to address both general addiction issues that can inherently target multiple substances and to address the specific overlapping conditions that patients experience.

While polysubstance use patterns have been present for many years, as the number of drugs available to users increases (i.e. with development of more synthetic substances), there may be more current opportunities for polysubstance use than in the past, and more may be forthcoming, with resulting morbidity and mortality. The fact that many (and perhaps most) persons with an OUD use multiple substances (both over their life course and simultaneously in specific drug-using episodes) makes it imperative to learn more about polysubstance use and its consequences.³⁹ Consequently, research on the co-use of opioids with multiple other substances is needed across the spectrum of prevention and treatment interventions, overdose reversal, public health surveillance, and basic neurobiology.

Acknowledgment

The authors acknowledge Eric Wargo for providing help with reviewing drafts of this Perspective.

References

- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2018. NCHS Data Brief, no 356. Hyattsville, MD: National Center for Health Statistics 2020.
- Case A, Deaton A. Mortality and morbidity in the 21st century. *Brookings Pap Econ Act* 2017;397–476. [PubMed: 29033460]
- Dowell D, Arias E, Kochanek K, Anderson R, Guy GP, Losby J, et al. Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000–2015. *JAMA* 2017;318(11):1065–1067. [PubMed: 28975295]
- Cranston K, Alpren C, John B, Dawson E, Roosevelt K, Burrage A, et al. Notes from the field: HIV diagnoses among persons who inject drugs - Northeastern Massachusetts, 2015–2018. *Morb Mortal Wkly Rep* 2019;68(10):253–254.
- Compton WM, Jones CM. Epidemiology of the U.S. opioid crisis: the importance of the vector. *Ann N Y Acad Sci* 2019;1451(1):130–143. [PubMed: 31378974]
- Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. Incidence of neonatal abstinence syndrome — 28 States, 1999–2013. *MMWR* 2016;65:799–802. [PubMed: 27513154]
- Zibbell JE, Asher AK, Patel RC, Kupronis, Iqbal BK, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. *Am J Public Health*. 2018;108(2):175–181. [PubMed: 29267061]
- Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. HIV infection linked to injection use of oxycodone in Indiana, 2014–2015. *N Engl J Med*. 2016;375:229–239. [PubMed: 27468059]
- Jackson KA, Bohm MK, Brooks JT, Asher A, Nadle J, Bamberg, et al. See I. Invasive methicillin-resistant staphylococcus aureus infections among persons who inject drugs - six sites, 2005–2016. *MMWR* 2018;67(22):625–628. [PubMed: 29879096]
- Council on Economic Advisers. The Underestimated Cost of the Opioid Crisis. 2017 Available at: <https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The%20Underestimated%20Cost%20of%20the%20Opioid%20Crisis.pdf>. Accessed November 26, 2018.
- Compton WM, Jones CM, Baldwin GT. Understanding the relationship between prescription opioid and heroin abuse. *New Eng J Med* 2016;374:154–163 [PubMed: 26760086]
- Jones CM, Campopiano M, Baldwin G, McCance-Katz EF. National and state treatment need and capacity for opioid agonist medication-assisted treatment. *Am J Public Health* 2015;105(8):55–63.

13. Jones CM, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waived to prescribe buprenorphine for the treatment of opioid use disorder. *Addiction* 2019;114(3):471–482. [PubMed: 30194876]
14. National Academies of Science, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: National Academies Press 2019.
15. Schwartz RP, Gryczynski J, O’Grady KE, Sharfstein JM, Warren G, Olsen Y, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. *Am J Public Health* 2013;103(5):917–22. [PubMed: 23488511]
16. Centers for Disease Control and Prevention. Evidence-Based Strategies for Preventing Opioid Overdose: What’s Working in the United States. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2018 Available from <http://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf>. Accessed March 26, 2019.
17. Compton WM, Wargo EM. Prescription drug monitoring programs: promising practices in need of refinement. *Ann Intern Med* 2018;168:826–827. [PubMed: 29801101]
18. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. *MMWR* 2016;65(1):1–49.
19. Lin HC, Wang Z, Boyd C, Simoni-Wastili L, Buu A. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. *Addictions Behaviors* 2018;76:348–35.
20. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. *Ann Intern Med* 2013;158(1):1–9. [PubMed: 23277895]
21. Jones CM, Lurie PG, Compton WM. Increase in Naloxone Prescriptions Dispensed in US Retail Pharmacies Since 2013. *Am J Public Health* 2016;106(4):689–690. [PubMed: 26890174]
22. Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM. Multiple naloxone administrations among emergency medical service providers is increasing. *Prehosp Emerg Care* 2017;21(4):411–419. [PubMed: 28481656]
23. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. *BMJ* 2013;346:f174. [PubMed: 23372174]
24. Walley AY, Green TC. Mainstreaming naloxone through coprescription to patients receiving long-term opioid therapy for chronic pain. *Ann Intern Med* 2016;165(4):292–293. [PubMed: 27367047]
25. Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. *MMWR* 2015;64(48):1137–1141.
26. MacArthur GJ, Van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. *Intl J Drug Policy* 2014;25(1):34–52.
27. Fast Track Action Committee on Health Science and Technology Response to the Opioid Crisis of the Committee on Science, National Science and Technology Council. Health research and development to stem the opioid crisis: a national roadmap. 2019 Available at: <https://www.whitehouse.gov/wp-content/uploads/2019/10/Health-Research-and-Development-for-Opioid-Crisis-National-Roadmap-2019.pdf> Accessed January 12, 2020.
28. Collins FS, Koroshetz WJ, Volkow ND. Helping to End Addiction Over the Long-term: The Research Plan for the NIH HEAL Initiative. *JAMA* 2018;320(2):129–130. [PubMed: 29896636]
29. Robins L, Compton W, Horton J. Is heroin the worst drug? Implications for drug policy. *Addiction Research & Theory* 2000;8(6):527–547.
30. Robins LN, Helzer JE, Davis DH. Narcotic use in Southeast Asia and afterward: an interview study of 898 Vietnam returnees. *Arch Gen Psychiatry*. 1975;32(8):955–961. [PubMed: 1156114]
31. Egger GB, Webb RA, Reynolds I. Early adolescent antecedents of narcotic abuse. *International Journal of the Addictions* 1978;13(5):773–781.
32. Frankel SI, Morgan DW, Greden JF. Heroin use among soldiers in the United States and Vietnam. *International Journal of the Addictions* 1977;12:1143–1154.

33. Inciardi JA, Pottieger AE. Drug use and street crime in Miami, an (almost) twenty-year retrospective. *Substance Use and Misuse* 1998;33:1839–1870. [PubMed: 9718182]
34. Hser YL, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. *Arch Gen Psychiatry* 2001;58(5):503–508. [PubMed: 11343531]
35. Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003–2013. *JAMA* 2015;314(14):1468–1478. [PubMed: 26461997]
36. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 national survey on drug use and health. *Ann Intern Med*. 2017;167(5):293–301. [PubMed: 28761945]
37. Han B, Compton WM, Blanco C, Jones CM. Correlates of prescription opioid use, misuse, use disorders, and motivations for misuse among US adults. *J Clin Psychiatry*. 2018;79(5):17m11973.
38. Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. *Drug Alcohol Depend* 2019;197:78–82. [PubMed: 30784952]
39. Hassan Ahmed N, Le Foll B. Polydrug use disorders in individuals with opioid use disorder. *Drug and Alcohol Dependence* 2019;198:28–33, ISSN 0376–8716, [PubMed: 30877954]
40. Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. *Int J Drug Policy*. 2017;49:32–40. [PubMed: 28888099]
41. Jones CM, Underwood N, Compton WM. Increases in Methamphetamine Use among Heroin Treatment Admissions in the United States, 2007–2016. *Addiction*. 2020; 115(2):347–353. [PubMed: 31503384]
42. Han B, Compton WM, Blanco C, DuPont RL. National Trends in Substance Use and Use Disorders Among Youth. *Journal of the American Academy of Child & Adolescent Psychiatry* 2017;56(9):747–754. [PubMed: 28838579]
43. Substance Abuse and Mental Health Services Administration. Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration Available at: <https://www.samhsa.gov/data/>. Accessed July 21, 2020.
44. Garland EL, Froeliger B, Zeidan F, Partin K, Howard MO. The downward spiral of chronic pain, prescription opioid misuse and addiction: cognitive, affective and neuropsychopharmacologic pathways. *Neurosci Biobehav Rev*.2013;37:2597–2607. [PubMed: 23988582]
45. John WS, Wu LT. Chronic non-cancer pain among adults with substance use disorders: prevalence, characteristics, and association with opioid overdose and healthcare utilization. *Drugs and Alcohol Dependence* 2020;209:107902.
46. Votaw VR, Witkiewitz K, Vowles KE, Weiss RD, Griffin ML, McHugh KR. Pain interference and catastrophizing are not associated with polysubstance use among treatment-seeking patients with substance use disorders and chronic pain. *Am J Drug and Alcohol Abuse* 2020 6 12:1–9. doi: 10.1080/00952990.2020.1757687. Epub ahead of print.
47. Compton WM, Han B, Blanco C, Johnson K, Jones CM. Correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the U.S. *Am J Psychiatry* 2018;175:741–755. [PubMed: 29656665]
48. Blanco C, Han B, Compton WM, Crane E, Lee J, Jones CM. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the U.S. *J Clin Psychiatry* 2018;8(6):18m12174.
49. Hunt DE, Lipton DS, Goldsmith D, Strug D. Street pharmacology: uses of cocaine and heroin in the treatment of addiction. *Drug and Alcohol Dependence* 1984;13:375–387. Smith, JE, Co, C., [PubMed: 6479016]
50. Leri F, Bruneau J, Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. *Addiction* 2003;98:7–22. [PubMed: 12492751]
51. Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. *Am J Prev Med*. 2015;49(4):493–501. [PubMed: 26143953]

52. Shah NG, Lathrop SL, Reichard RR, Landen MG. Unintentional drug overdose death trends in New Mexico, USA, 1990–2005: combinations of heroin, cocaine, prescription opioids and alcohol. *Addiction* 2008;103:126–136. [PubMed: 18028518]
53. Florida Drug Related Surveillance and Tracking System. 2020 Polysubstance deaths with fentanyl in 2017. Available at: https://public.tableau.com/views/FloridaDrug-RelatedOutcomesSurveillanceandTrackingSystem/FDLE-MECPolysubstance?%3Aembed=y&%3A%20display_count=no&%3AshowVizHome=no Accessed March 27, 2020.
54. Darke S, Marela C, Mills KL, Rossa J, Slade T, Burns L, et al. Patterns and correlates of non-fatal heroin overdose at 11-year follow-up: Findings from the Australian Treatment Outcome Study. *Drug and Alcohol Dependence* 2014;144:148–152. [PubMed: 25278146]
55. Darke S Heroin overdose. *Addiction* 2016;111:2060–2063 [PubMed: 27511799]
56. Kandel DB, Hu MC, Griesler P, Wall M. Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances. *Drug and Alcohol Dependence* 2017;178:501–511. [PubMed: 28719884]
57. Bohnert ASB, Valenstein M, Blair MJ, Ganoczy D, McCarthy JF, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. *JAMA* 2011;305(13):1315–1321. [PubMed: 21467284]
58. Jones CM, Paulozzi LJ, Mack KA. Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United States, 2010. *MMWR* 2014;63(40):881–885. [PubMed: 25299603]
59. Pennings EJ, Leccese AP, Wolff FA. Effects of concurrent use of alcohol and cocaine. *Addiction* 2002;97:773–783. [PubMed: 12133112]
60. Jones CM, Einstein E, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016. *JAMA* 2018;319(17):1819–1821. [PubMed: 29715347]
61. Carroll JJ, Marshall BDL, Rich JD, Green TC. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study. *Int J Drug Policy* 2017;46:136–145. [PubMed: 28578864]
62. Gaudreault P, Guay J, Thivierge RL, Verdy I. Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment. *Drug Safety* 1991;6:247–65. [PubMed: 1888441]
63. Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. *Drug and Alcohol Dependence* 2012;125(1–2):8–18. [PubMed: 22857878]
64. Meacham MC, Roesch SC, Strathdee SA, Lindsay S, Gonzalez-Zuniga P, Gaines TL. Latent classes of polydrug and polyroute use and associations with human immunodeficiency virus risk behaviours and overdose among people who inject drugs in Tijuana, Baja California, Mexico. *Drug and Alcohol Review* 2018;37:128–136. [PubMed: 28337798]
65. Jordan A, Salen P, Wojda TR, Coher MS, Hasani A, Luster J, et al. Exploring the association between initial serum alcohol concentration and polysubstance use: More than a simple “gateway drug” effect? *Int J Crit Illn Inj Sci* 2018;8(4):201–206. [PubMed: 30662866]
66. Koob GF. Hedonic valence, dopamine and motivation. *Mol Psychiatry* 1996;1:186–189. [PubMed: 9118342]
67. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. *J Neurosci* 1992;12:483–488. [PubMed: 1346804]
68. Hemby SE, Co C, Dworkin SI, Smith JE. Synergistic elevations in nucleus accumbens extracellular dopamine concentrations during self-administration of cocaine/heroin combinations (Speedball) in rats. *J Pharmacol Exp Ther* 1999;288:274–280 [PubMed: 9862781]
69. Pattison LP, McIntosh S, Budygin EA, Hemby SE. Differential regulation of accumbal dopamine transmission in rats following cocaine, heroin and speedball self-administration. *J Neurochem* 2012;122:138–146. [PubMed: 22443145]
70. Korpi ER, den Hollander B, Farooq U, Vashchinkina E, Rajkumar R, Nutt DJ, et al. Mechanisms of action and persistent neuroplasticity by drugs of abuse. *Pharmacol Rev* 2015;67:872–1004. [PubMed: 26403687]

71. Bocklisch C, Pascoli V, Wong JC, House DR, Yvon C, de Roo M, et al. Cocaine disinhibits dopamine neurons by potentiation of GABA transmission in the ventral tegmental area. *Science* 2013;341:1521–1525. [PubMed: 24072923]
72. Robinson JB. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. *Biochem Pharmacol* 1985;34:4105–4108. [PubMed: 3933519]
73. Smith JE, Co C, Collier MD, Hemby SE, Martin TJ. Self-administered heroin and cocaine combinations in the rat: additive reinforcing effects-supra-additive effects on nucleus accumbens extracellular dopamine. *Neuropsychopharmacology* 2006;31:139–150. [PubMed: 15956989]
74. Foltin RW, Fischman MW. The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. *J Pharmacol Exp Ther* 1992;261:623–632. [PubMed: 1578376]
75. Foltin RW, Christiansen I, Levin FR, Fischman MW. Effects of single and multiple intravenous cocaine injections in humans maintained on methadone. *J Pharmacol Exp Ther* 1995;275:38–47. [PubMed: 7562574]
76. Negus SS, Gatch MB, Mello NK. Discriminative stimulus effects of a cocaine/heroin “speedball” combination in rhesus monkeys. *J Pharmacol Exp Ther* 1998;285:1123–1136. [PubMed: 9618415]
77. Verrico CD, Miller GM, Madras BK. MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. *Psychopharmacology (Berl)* 2007;189:489–503. [PubMed: 16220332]
78. Kalivas PW, Duffy P, Eberhardt H. Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. *J Pharmacol Exp Ther* 1990;253:858–866. [PubMed: 2160011]
79. Okada H, Matsushita N, Kobayashi K, Kobayashi K. Identification of GABAA receptor subunit variants in midbrain dopaminergic neurons. *J Neurochem* 2004;89:7–14. [PubMed: 15030384]
80. Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM, et al. Neural bases for addictive properties of benzodiazepines. *Nature* 2010;463:769–774. [PubMed: 20148031]
81. Laroche MR, Liebschutz JM, Zhang F, Ross-Degnan D, Wharam JF. Opioid prescribing after nonfatal overdose and association with repeated overdose: a cohort study. *Ann Intern Med* 2016;164(1):1–9. [PubMed: 26720742]
82. Afzal A, Kiyatkin EA. Interactions of benzodiazepines with heroin: respiratory depression, temperature effects, and behavior. *Neuropharmacology* 2019;158:107677. [PubMed: 31228487]
83. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. *Nature* 1998;391:173–177. [PubMed: 9428762]
84. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. *Nature* 1997;390:401–404. [PubMed: 9389479]
85. Grenhoff J, Aston-Jones G, Svensson TH. Nicotinic effects on the firing pattern of midbrain dopamine neurons. *Acta Physiol Scand* 1986;128:351–358. [PubMed: 3788613]
86. Jones IW, Wonnacott S. Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. *J Neurosci* 2004;24:11244–11252. [PubMed: 15601930]
87. Livingstone PD, Wonnacott S. Nicotinic acetylcholine receptors and the ascending dopamine pathways. *Biochem Pharmacol* 2009;78:744–755. [PubMed: 19523928]
88. Palmatier MI, Evans-Martin FF, Hoffman A, Caggiula AR, Chaudhri N, Donny EC, et al. Dissociating the primary reinforcing and reinforcement-enhancing effects of nicotine using a rat self-administration paradigm with concurrently available drug and environmental reinforcers. *Psychopharmacology (Berl)* 2006;184:391–400. [PubMed: 16249908]
89. Perkins KA, Karelitz JL, Boldry MC. Nicotine acutely enhances reinforcement from non-drug rewards in humans. *Front Psychiatry* 2017;8:65. [PubMed: 28507522]
90. DuPont RL, Han B, Shea CL, Madras BK. Drug use among youth: national survey data support a common liability of all drug use. *Preventive Medicine* 2018;113:68–73. [PubMed: 29758306]
91. Kandel DB, Kandel ER. The Gateway Hypothesis of substance abuse: developmental, biological and societal perspectives. *Acta Paediatrica* 2015;104:130–137. [PubMed: 25377988]

92. Joseph MH, Peters SL, Prior A, Mitchell SN, Brazell MP, Gray JA. Chronic nicotine administration increases tyrosine hydroxylase selectivity in the rat hippocampus. *Neurochem Int* 1990;16:269–273. [PubMed: 20504567]
93. Mitchell SN, Smith KM, Joseph MH, Gray JA. Increases in tyrosine hydroxylase messenger RNA in the locus coeruleus after a single dose of nicotine are followed by time-dependent increases in enzyme activity and noradrenaline release. *Neuroscience* 1993;56:989–997. [PubMed: 7904333]
94. Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. *Neuron* 2003;37:577–582. [PubMed: 12597856]
95. Hill R, Roberts J, Maclachlan J, Dewey W, Kelly E, Henderson G. Prolonged ethanol administration prevents the development of tolerance to morphine-induced respiratory depression. *Drug and Alcohol Dependence* 2019;205:107674. [PubMed: 31715438]
96. Volkow ND, Koob GF, Croyle RT, Bianchi DW, Gordon JA, et al. The conception of the ABCD study: from substance use to a broad NIH collaboration. *Developmental Cognitive Neuroscience* 2018;32:4–7. [PubMed: 29051027]
97. Xie XQ, Wang L, Liu H, Ouyang Q, Fang C, Su W. Chemogenomics knowledgebased polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands. *Front Pharmacol* 2014;5:3. [PubMed: 24567719]
98. Cheng J, Wang S, Lin W, Wu N, Wang Y, Chen M, et al. Computational Systems Pharmacology-Target Mapping for Fentanyl-Laced Cocaine Overdose. *ACS Chem Neurosci* 2019;10:3486–3499. [PubMed: 31257858]
99. Compton WM, Jones CM, Baldwin GT, Harding FM, Blanco C, Wargo EM. Targeting youth to prevent later substance use disorder: an underutilized response to the US opioid crisis. *Am J Pub Health* 2019;109(S3):S185–S189. [PubMed: 31242006]
100. Mackey S, Allgaier N, Chaarani B, Spechler P, Orr C, Bunn J, et al. Mega-Analysis of Gray Matter Volume in Substance Dependence: General and Substance-Specific Regional Effects. *Am J Psychiatry* 2019;176:119–128. [PubMed: 30336705]




Figure 1:

Weighted lifetime prevalence of substance use and mean number of other substances ever used by adults age 18 and older in the United States (n=51,000; Source: 2018 U.S. National Survey on Drug Use and Health [adapted from Eric Wish, University of Maryland, Center for Substance Abuse Research])




Figure 2:

Rat brain neurochemical neurocircuits in drug reward (From: Koob GF, Volkow ND. Neurocircuitry of Addiction. *Neuropsychopharmacology* 2010;35:217–238.)

Sagittal section through a representative rodent brain illustrating the pathways and receptor systems implicated in the acute reinforcing actions of drugs of abuse. Cocaine and amphetamines activate the release of dopamine in the nucleus accumbens and amygdala through direct actions on dopamine terminals. Opioids activate opioid receptors in the VTA, nucleus accumbens, and amygdala through direct or indirect actions via interneurons. Opioids facilitate the release of dopamine in the nucleus accumbens by an action either in the VTA or the nucleus accumbens, but also are hypothesized to activate elements independent of the dopamine system. Alcohol activates g-aminobutyric acid-A (GABAA) receptors or GABA release in the VTA, nucleus accumbens, and amygdala by either direct actions at the GABAA receptor or through indirect release of GABA. Alcohol is hypothesized to facilitate the release of opioid peptides in the VTA, nucleus accumbens, and central nucleus of the amygdala. Alcohol facilitates the release of dopamine in the nucleus accumbens through an action either in the VTA or the nucleus accumbens. Nicotine activates nicotinic acetylcholine receptors in the VTA, nucleus accumbens, and amygdala, either directly or indirectly, through actions on interneurons. Cannabinoids activate cannabinoid CB1 receptors in the VTA, nucleus accumbens, and amygdala. Cannabinoids facilitate the release of dopamine in the nucleus accumbens through an unknown mechanism either in the VTA or the nucleus accumbens. The blue arrows represent the interactions within the extended amygdala system hypothesized to have a key function in drug reinforcement. The

medial forebrain bundle represents ascending and descending projections between the ventral forebrain (nucleus accumbens, olfactory tubercle, septal area) and the ventral midbrain (VTA) (not shown in figure for clarity). AC, anterior commissure; AMG, amygdala; ARC, arcuate nucleus; BNST, bed nucleus of the stria terminalis; Cer, cerebellum; C-P, caudate-putamen; DMT, dorsomedial thalamus; FC, frontal cortex; Hippo, hippocampus; IF, inferior colliculus; LC, locus coeruleus; LH, lateral hypothalamus; N Acc., nucleus accumbens; OT, olfactory tract; PAG, periaqueductal gray; RPn, reticular pontine nucleus; SC, superior colliculus; SNr, substantia nigra pars reticulata; VP, ventral pallidum; VTA, ventral tegmental area.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript